This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.
Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.
Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs?
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.
Is Avanos Medical (AVNS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Avanos Medical (AVNS) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.
Philips' (PHG) Lung Suite 3D Imaging Solution Gains Traction
by Zacks Equity Research
Philips' (PHG) innovative lung cancer diagnosis and treatment solution, Philips Lung Suite, is witnessing rapid adoption by clinical partners globally
Philips (PHG) Ties Up With Nuvo Group to Boost Maternal Care
by Zacks Equity Research
Philips (PHG) collaborates with Nuvo to develop maternity care services with digital solutions and eco-system building in rural areas
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New Strong Buy Stocks for March 11th
by Zacks Equity Research
ABM, AVNS, ASIX, AA, and ESEA have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2022.
Does Avanos Medical (AVNS) Have the Potential to Rally 26% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Avanos Medical (AVNS) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 24th
by Zacks Equity Research
AGNC, AVNS, and SQ have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2022
Intuitive Surgical, Inc. (ISRG) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 1.56% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Avanos Medical's (AVNS) App to Support Pain Management Process
by Zacks Equity Research
Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.
Avanos Medical (AVNS) Down 17.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -7.41% and 0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Avanos Medical (AVNS) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?
by Zacks Equity Research
Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.